Combination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancer

To establish the toxicities and maximum tolerated dose (MTD) of nedaplatin with gemcitabine, and to observe their antitumour activity, we conducted a combination phase I study in advanced non-small-cell lung cancer (NSCLC). Patients received nedaplatin (60–100 mg m(−2) given intravenously over 90 mi...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Kurata, T, Tamura, K, Yamamoto, N, Nogami, T, Satoh, T, Kaneda, H, Nakagawa, K, Fukuoka, M
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2004
Témata:
Clinical
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2409510/
https://ncbi.nlm.nih.gov/pubmed/15150564
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6601817
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky